ES2972783T3 - Tratamiento de las neoplasias malignas hematológicas - Google Patents

Tratamiento de las neoplasias malignas hematológicas

Info

Publication number
ES2972783T3
ES2972783T3 ES18743104T ES18743104T ES2972783T3 ES 2972783 T3 ES2972783 T3 ES 2972783T3 ES 18743104 T ES18743104 T ES 18743104T ES 18743104 T ES18743104 T ES 18743104T ES 2972783 T3 ES2972783 T3 ES 2972783T3
Authority
ES
Spain
Prior art keywords
treatment
hematological malignancies
hematological
malignancies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18743104T
Other languages
English (en)
Inventor
Marieke Griffioen
J H Frederik Falkenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2019156A external-priority patent/NL2019156B1/en
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Application granted granted Critical
Publication of ES2972783T3 publication Critical patent/ES2972783T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18743104T 2017-06-30 2018-06-28 Tratamiento de las neoplasias malignas hematológicas Active ES2972783T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2019156A NL2019156B1 (en) 2017-06-30 2017-06-30 Treatment of haematological malignancies
NL2020602 2018-03-16
PCT/NL2018/050421 WO2019004831A1 (en) 2017-06-30 2018-06-28 TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Publications (1)

Publication Number Publication Date
ES2972783T3 true ES2972783T3 (es) 2024-06-17

Family

ID=62976114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18743104T Active ES2972783T3 (es) 2017-06-30 2018-06-28 Tratamiento de las neoplasias malignas hematológicas

Country Status (8)

Country Link
US (1) US11352389B2 (es)
EP (2) EP3645560B1 (es)
JP (2) JP2020530274A (es)
KR (1) KR20200023311A (es)
CN (1) CN111032686B (es)
CA (1) CA3067772A1 (es)
ES (1) ES2972783T3 (es)
WO (1) WO2019004831A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111865UA (en) * 2019-05-01 2021-11-29 Pact Pharma Inc Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
IL296241A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Compositions and methods for immunotherapy for npm1c-positive cancer
CN113082211A (zh) * 2021-04-14 2021-07-09 南方医科大学珠江医院 一种治疗npm1突变急性髓系白血病的药物组合物及其应用
WO2023219510A1 (en) * 2022-05-13 2023-11-16 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
EP4368189A1 (en) * 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
ITRM20040534A1 (it) * 2004-10-29 2005-01-29 Brunangelo Falini Mutanti della proteina nucleofosmina (npm), sequenze geniche corrispondenti e relativi usi.
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
WO2009061182A1 (en) * 2007-11-05 2009-05-14 Leiden University Medical Center Hla class ii pi4k2b mhags and application thereof
BR112013006718B1 (pt) * 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
CN102775495A (zh) * 2011-05-12 2012-11-14 北京大学第一医院 多肽混合物、t细胞疫苗及其应用
WO2015163778A1 (en) * 2014-04-22 2015-10-29 Chudakov Dmitry Mikhajlovich Method to identify hot spot pcr and sequencing errors in highthroughput sequencing data
JP6712261B2 (ja) * 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
AU2016264623B2 (en) * 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens

Also Published As

Publication number Publication date
US20200123200A1 (en) 2020-04-23
EP3645560B1 (en) 2023-12-20
CA3067772A1 (en) 2019-01-03
EP4327819A2 (en) 2024-02-28
KR20200023311A (ko) 2020-03-04
US11352389B2 (en) 2022-06-07
EP3645560A1 (en) 2020-05-06
WO2019004831A8 (en) 2022-10-13
JP2023116601A (ja) 2023-08-22
JP2020530274A (ja) 2020-10-22
WO2019004831A1 (en) 2019-01-03
CN111032686A (zh) 2020-04-17
EP4327819A3 (en) 2024-05-29
CN111032686B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA41997A (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
ES2972783T3 (es) Tratamiento de las neoplasias malignas hematológicas
MA41449A (fr) Polythérapies pour le traitement de cancers
MA46180A (fr) Analogues de l'amyline
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3283210T3 (da) Fremgangsmåde
MA47408A (fr) Traitement du cancer
DK2897382T3 (da) Forbedring af binaural kilde
FR3037803B1 (fr) Implant de substitution du sternum
DK3073409T3 (da) Maskering af forskellige indholdstyper
DK3576740T3 (da) Cancerbehandling
FR3022129B1 (fr) Baignoire de puericulture
ES1137506Y (es) Helice reductora de perdidas
FR3024647B1 (fr) Transat de puericulture
DK3275315T3 (da) Fileteringsindretning
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
DK3302499T3 (da) Behandling af mitokondrielle sygdomme
DK3285588T3 (da) Fremgangsmåde
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
FI20145980A (fi) Kompleksisen sulfidirikasteen käsittely
FR3035458B1 (fr) Capuchon de fixation rotule
FI20155387A (fi) Sterolien tuottaminen